EXPERTISE
- Clinical
and regulatory consulting services to the biotechnology
industry, pharmaceutical industry and academia.
- Consultation
regarding clinical and public health issues as they pertain
to the development of new products and clinical trials
- Providing
clinical development plans for early phase biologics and
drugs
- Comprehensive
FDA style review of PIND, IND, BLA, and NDA submissions
- Design,
preparation and implementation of Phase 1, 2, 3 and 4 clinical
triala
- Clinical
protocol development
- Assistance
with GCP compliance
- Comprehensive
review of safety and efficacy data
- Medical
monitoring
- Assistance
with the conduct of clinical trials, including consent forms,
case report forms, IRBs, DSMBs, selection of investigators,
safety monitoring and reporting
- Preparation
for FDA meetings and advisory committees
- CRO
oversight for ongoing studies
|
EDUCATION:
| M.S. |
|
Public
Health (MPH) George Washington University, Washington,
DC (1992) |
| |
|
Trinity
College of Music, London, England, Non-Degree Program
in Violin Performance
(1982-1983) |
| M.D. |
|
Northwestern
University School of Medicine, Chicago, IL (1987) |
| B.A. |
|
Smith
College, Northampton, MA; Biology cum laude (1982) |
EXPERIENCE:
(Regulatory and Product Development Experience)
CURRENT
POSITION: |
|
Senior
Clinical Consultant, Biologics
Consulting Group, Inc.
Evergreen, CO. |
Dec.
2004 to
present |
|
Provide
clinical and regulatory consulting services to the biotechnology
industry, pharmaceutical industry and academia. Five years
of experience as a clinical reviewer at the FDA, in addition
to my training in Internal Medicine and Public Health,
enhances my ability to consult in a number of clinical
and regulatory areas. |
| |
|
|
| 1998
- Nov. 2004 |
|
Affiliate, Biologics
Consulting Group, L.L.C.
Evergreen, CO. |
| |
|
|
| 1998
- Dec. 2004 |
|
Clinical
and Regulatory Consultant
Evergreen, CO |
| |
|
|
| 1999
- 2004 |
|
SouthPark
Internal Medicine
Littleton, CO
- Practice
of Internal Medicine
|
| |
|
|
| 1998 |
|
Women's
Health Specialists
Denver, CO.
- Practice
of Internal Medicine
|
| |
|
|
| 1997 |
|
Part-time
staff physician, National Naval Medical Center,
Department of Medicine,
Bethesda, MD.
- Precepted
a Physical Diagnosis course for first year medical
students
|
| |
|
|
| 1992
- 1997 |
|
Senior
Clinical Reviewer, Food and Drug Administration,
Center for Biologics Evaluation and Research (CBER),
Office of Vaccines Research and Review, Division of
Vaccines and Related Products Applications, Clinical
Trials Branch
Bethesda, MD.
IND
Review:
- Responsible
for the comprehensive review of protocols for Phase
1, 2 and 3 clinical studies.
- Assessed
the rationale, safety and design of clinical studies
submitted to over 80 INDs (Investigational New Drug
Applications) for bacterial, viral (including HIV)
and DNA vaccines, as well as several biological therapeutic
products.
- It
was my recommendation which determined whether a study
was allowed to proceed or placed on clinical hold.
- Responsible
for training new physicians who joined our Division.
PLA/BLA
Review:
- Responsible
for the review of clinical data submitted in PLAs
(Product License Applications) to support the licensure
of new vaccines and other biological products.
- Performed
a complete review of all clinical data submitted and
then formally presented my conclusions and recommendations
at an FDA Advisory Committee.
Guidance
to Industry:
- Provided
guidance regarding the overall clinical development
of investigational products, including such topics
as the type and quantity of preclinical data necessary
to initiate Phase 1 studies, the need for dose-ranging
studies, the choice of efficacy endpoints for pivotal
Phase 3 trials, and the size of the safety database
necessary for licensure.
Policy
and Regulatory Document Development:
- Participated
in a variety of special FDA projects and committees
ranging from combination pediatric vaccines to HIV
vaccines to the inclusion of women in clinical trials.
- Served
on many FDA policy committees and participated in
the writing and review of regulatory documents.
|
| |
|
|
| 1993
- 1995 |
|
Part-time
staff physician, National Cancer Institute, Division
of Cancer Treatment, Medicine Branch, Retroviral Diseases
Section, HIV Clinic.
Bethesda, MD.
- Assisted
in conducting Phase 1 and 2 studies of HIV therapeutics.
|
| |
|
|
| 1990
- 1992 |
|
Fellowship
in General Internal Medicine, George Washington
University, Department of Health Care Sciences.
Washington, DC |
| |
|
|
| 1987
- 1990 |
|
Internship
and Residency in Internal Medicine, University of
Minnesota
Minneapolis, MN |
AWARDS:
| 1997 |
|
FDA
Commendable Service Award for superior performance in
the clinical review of vaccine and therapeutic products. |
CERTIFICATIONS:
| 2000 |
|
American
Board of Internal Medicine Recertification |
| 1990 |
|
American
Board of Internal Medicine |
| 1988 |
|
National
Board of Medical Examiners |
MEDICAL
LICENSURE:
| 1997-present |
|
Colorado
(inactive status since 2005) |
| 1991
- 1997 |
|
Maryland |
| 1990
- 1992 |
|
District
of Columbia |
| 1989
- 1990 |
|
Minnesota |
COMMITTEE
MEMBERSHIP:
| 2004-present |
|
Member of NIH review committee
for the Vaccine Treatment and Evaluation Units (VTEUs
for HIV vaccine and treatment studies)
|
| 1997 |
|
Member
of the FDA Pregnancy Registry Working Group that evaluated
product labeling pertaining to the use of drugs and biologics
during pregnancy. |
1994-1997 |
|
Reviewer
of documents from Second International Conference on Harmonization
(ICH). |
| 1994-1997 |
|
FDA
representative on the AIDS Clinical Trials Group (ACTG)
HIV Specific Immunity Subcommittee of the Pediatric Vaccine
Committee. |
| 1994-1995 |
|
Member
of the FDA Information Standards Steering Committee's
Clinical Laboratory Data Working Group. |
| 1994 |
|
Member
of an FDA committee that discussed issues and policy regarding
the inclusion of women in clinical trials. |
| 1993-1994 |
|
Member
of an FDA committee that produced the document entitled
"Evaluation of Combination Vaccines: Production,
Testing and Clinical Study". |
PRESENTATIONS
& CONFERENCES:
| Aug 2008 |
|
Presentation at CHI’s conference “Clinical Risk Management and Safety for Vaccines” entitled “Clinical and Regulatory Considerations for the Development of Vaccines.” Boston, MA. |
| Mar 2007 |
|
Presentation at the World Vaccine Congress 2007 entitled “Clinical Development Considerations for Vaccines.” Washington, DC. |
| Oct
2005 |
|
Presentation
at bioLOGIC 2005 entitled "Clinical Development of
Biodefense Vaccines." Boston, MA. |
| 1999-present |
|
Multiple
presentations to clients regarding Good Clinical Practices
(GCP) |
| July
1999 |
|
Presentation
entitled "Establishing and Using Serological Correlates
of Protection" and "Preparation and Use of Documents
to Support Clinical Trials." Pentagon City, VA. |
| May
1997 |
|
Presentation
entitled "Adverse Event Reporting: What, When and
How? A Vaccine Perspective." Walter Reed Army Medical
Center. Silver Spring, MD. |
| July
1996 |
|
Presentation
before the FDA's Vaccines and Related Biological Products
Advisory Committee (CBER) in which I discussed clinical
data submitted to support an acellular DTP vaccine. This
new pediatric vaccine was approved by FDA. Rockville,
MD. |
| Apr.
1996 |
|
Presentation
on the topic of IND Clinical Review at a conference entitled
"Regulatory Issues Related to Novel Product and Process
Technologies." This conference was sponsored by the
Pacific Region biotechnology industry in conjunction with
the Food and Drug Administration. Irvine, CA. |
| Nov.
1995 |
|
Co-chair
at a conference entitled "Improving the Performance
of Influenza and Pneumococcal Vaccines in Adults."
This session addressed immunogenicity and safety issues
in influenza and pneumococcal vaccine development. Washington,
DC. |
| May
1993 |
|
Presentation
before the FDA's Antiviral Drugs Advisory Committee (CDER)
in which I discussed clinical data submitted to support
the use of intravenous Immune Globulin (IVIG) to prevent
bacterial infections in HIV-infected children. This new
indication for IVIG was approved by the FDA. Rockville,
MD. |
RESEARCH
AND PUBLICATIONS:
2008 |
|
AA McCormick, S Reddy, SF Reinl, TI Cameron, DK Czerwinski, F Voljdani, KM Hanley, SJ Garger, EL White, J Novak, J Barrett, RB Holtz, D Tuse, R Levy (2008). Plant-produced idiotype vaccines for the treatment of non-Hodgkin’s lymphoma: Safety and immunogenicity in a phase I clinical study. PNAS: 105 (29): 10131-10136. |
1997 |
|
Book
chapter entitled "The Biological IND" Biologics
Development: A Regulatory Overview, Authors: Jeanne Novak,
Julia Barrett, Loris McVittie and Donna Chandler, Editor:
Mark Mathieu, Published by Parexel International Corporation |
1997 |
|
Book
chapter entitled "The IND for Biological Products"
Global Biotechnology Product Registration: E.U., U.S.
and Japan, Authors: Jeanne Novak, Julia Barrett, Loris
McVittie, Donna Chandler and Mark Mathieu, Editor: Mark
Mathieu, Published by Parexel International Corporation |
1991
- 1992 |
|
National
Cancer Institute, Bethesda, MD, Division of Cancer Prevention
and Control, Early Detection and Community Oncology Program,
Epidemiological study examining rural-urban differences
in the stage at diagnosis of breast and cervical carcinoma |
| |
|
Page
Updated:
August 13, 2008
|
|
|